The combination of the MHRA Accreditation and the expert knowledge of conducting 500 Early Phase Studies ensure Richmond Pharmacology can provide you with a service that meets your needs.
Adaptive Phase I Studies
Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.
First transdermal patch to treat schizophrenia hits market
March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
.svg){kind=small}
